{
    "clinical_study": {
        "@rank": "107410", 
        "arm_group": [
            {
                "arm_group_label": "Placebo injection", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline"
            }, 
            {
                "arm_group_label": "GLYX-13, 5 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Low dose of GLYX-13"
            }, 
            {
                "arm_group_label": "GLYX-13, 10 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "High dose of GLYX-13"
            }
        ], 
        "brief_summary": {
            "textblock": "GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major\n      depressive disorder (depression) who have responded inadequately to another antidepressant\n      drug during the current episode.  This trial will assess the effects of GLYX-13 on\n      depression when added to another antidepressant drug that the patient is already taking."
        }, 
        "brief_title": "Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects\n\n          -  Aged 18 to 65 years\n\n          -  Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR)\n             criteria for major depressive disorder (MDD)\n\n          -  Current episode has lasted \u2265 8 weeks before Screening with an inadequate response\n             (<50% reduction in the Antidepressant Treatment Response Questionnaire [ATRQ]) to all\n             approved antidepressant agent(s) administered at an adequate dose and duration for\n             the current episode\n\n          -  Taking no antidepressant agent currently or taking an SSRI or SNRI from among the\n             following:  SSRI: SSRIs: citalopram, escitalopram, fluoxetine, fluvoxamine,\n             paroxetine, paroxetine CR, sertraline; SNRIs: desvenlafaxine, duloxetine,\n             venlafaxine, venlafaxine XR\n\n          -  HDRS-17 score \u2265 18 at screening.\n\n          -  HDRS-17 score \u2265 18 at predose baseline.\n\n          -  Female subjects of childbearing potential with a negative serum pregnancy test prior\n             to entry into the study and who are practicing an adequate method of birth control\n             (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and\n             who do not plan to become pregnant during the course of the study. Female subjects\n             may be included without a negative serum pregnancy test if they are surgically\n             sterile or at least 2 years post-menopausal.\n\n          -  Clinical laboratory values < 2 times the upper limit of normal (ULN) or deemed not\n             clinically significant per the investigator and Naurex medical monitor\n\n          -  Ability to understand the requirements of the study, provide written informed\n             consent, abide by the study restrictions, and agree to return for the required\n             assessments\n\n          -  Based on the investigator and Naurex medical monitor's clinical judgment, subjects\n             with eating disorders, obsessive compulsive disorder (OCD), panic disorder,\n             post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to\n             major depressive episodes (MDEs) are permitted.\n\n        Exclusion Criteria:\n\n          -  Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive\n             disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating\n             disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic\n             disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit\n             hyperactivity disorder (ADHD), or PTSD\n\n          -  A clinically significant current Axis II diagnosis of borderline, antisocial,\n             paranoid, schizoid, schizotypal, or histrionic personality disorder\n\n          -  Experiencing hallucinations, delusions, or any psychotic symptomatology in the\n             current episode; lifetime history of psychosis\n\n          -  Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures\n             or strokes\n\n          -  Currently hospitalized or residing in an in-patient facility during the study\n             participation\n\n          -  Substance abuse within the last 12 months, including greater than or equal to 5 units\n             of alcohol per day where 1 unit = \u00bd pint of beer, 1 glass of wine, or 1 oz. of\n             spirits consumed most weeks.\n\n          -  Women who are planning to become pregnant during the course of the study\n\n          -  Allergy or intolerance to current antidepressant or other current medications\n\n          -  Participation in any clinical trial of an investigational product or device within 30\n             days of enrollment in this trial with the exception of GLYX13-C-201.\n\n          -  Positive screen for drugs of abuse including cocaine, marijuana, phencyclidine (PCP),\n             ketamine (Special K), opioid, or other agent that the investigator feels is being\n             abused\n\n          -  Have received electroconvulsive therapy, transcranial magnetic stimulation (TMS), or\n             vagal nerve stimulation (VNS) for the current depressive episode\n\n          -  Pose current (past 6 months) suicide risk based on administration of the C SSRS and\n             the investigator's clinical judgment\n\n          -  Mass at screening visit of >120 kg\n\n          -  Human immunodeficiency virus (HIV) infection (based on the HIV-1 & HIV-2 antibody\n             screen) or other ongoing infectious disease\n\n          -  Females who are currently pregnant or planning to become pregnant during the course\n             of the study\n\n          -  Dextromethorphan or tramadol since these are serotonin uptake inhibitors\n\n          -  History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor\n             [NMDAR] ligands including ketamine, dextromethorphan, memantine, methadone,\n             dextropropoxyphene, or ketobemidone."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684163", 
            "org_study_id": "GLYX13-C-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GLYX-13, 5 mg/kg", 
                    "GLYX-13, 10 mg/kg"
                ], 
                "intervention_name": "GLYX-13", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antidepressive Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "depression", 
            "MDD", 
            "GLYX-13", 
            "HDRS-17", 
            "HAMD-17"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67211"
                    }, 
                    "name": "University of Kansas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08054"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Princeton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08540"
                    }, 
                    "name": "Global Medical Institutes LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10128"
                    }, 
                    "name": "Michael R Liebowitz MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phildadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "CRI Lifetree"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "Naurex, Inc", 
            "last_name": "Lee Bastin, RN Ed.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Hamilton Depression Rating Scale Score", 
            "safety_issue": "No", 
            "time_frame": "6 weeks, 12 weeks, 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684163"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Clinical Global Impression of Change", 
            "safety_issue": "No", 
            "time_frame": "6 weeks, 12 weeks, 16 weeks"
        }, 
        "source": "Naurex, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Naurex, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}